Rsch BE: Combined approaches for resection of extensive glomus jugular…
페이지 정보
본문
Rsch BE: Combined approaches for resection of extensive glomus jugulare tumors. A review of 12 cases. J Neurosurg 1994, 80:1026-1038. Pollock BE: Stereotactic radiosurgery in patients with glomus jugulare tumors. Neurosurg Focus 2004, 17(2):E10. Watkins LD, Mendoza N, Cheesman AD, Symon L: Glomus jugulare tumors: a review of 61 cases. Acta Neurochir (Wien) 1994, 130:66-70. Eustacchio S, Trummer M, Unger F, Schrottner O, Sutter B, Pendl G: The role of Gamma Knife radiosurgery in the management of glomus jugular tumors. Acta Neurochir Suppl 2002, 84:91-97. Schild SE, Foote RL, Buskirk SJ, Robinow JS, Bock FF, Cupps RE, Earle JD: Results of radiotherapy for chemodectomas. Mayo Clin Proc 1992, 67:537-540.doi:10.1186/1477-7819-8-76 Cite this article as: Hafez et al.: The safety and efficacy of gamma knife surgery in management of glomus jugulare tumor. World Journal of Surgical Oncology 2010 8:76.Submit your next manuscript to BioMed Central and take full advantage of:?Convenient online submission ?Thorough peer review ?No space constraints or color figure charges ?Immediate publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Research which is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submit
Bussone et al. Arthritis Research Therapy 2011, 13:R74 http://arthritis-research.com/content/13/3/RRESEARCH ARTICLEOpen AccessIdentification of new autoantibody specificities directed at proteins involved in the transforming growth factor b pathway in patients with systemic sclerosisGuillaume Bussone1,2, Hanadi Dib1,2, Mathieu C Tamby1,2, Cedric Broussard3, Christian Federici3, Genevi e Woimant4, Luc Camoin3, Lo Guillevin5 and Luc Mouthon1,2,5*AbstractIntroduction: Antinuclear antibodies (ANAs), usually detected by indirect immunofluorescence on HEp-2 cells, are identified in 90 of patients with RRx-001 systemic sclerosis (SSc). Thus, approximately 10 of SSc patients have no routinely detectable autoantibodies, and for 20 to 40 of those with detectable ANAs, the ANAs do not have identified specificity (unidentified ANAs). In this work, we aimed to identify new target autoantigens in SSc patients. Methods: Using a proteomic approach combining two-dimensional electrophoresis and immunoblotting with HEp-2 cell total and enriched nuclear protein extracts as sources of autoantigens, we systematically analysed autoantibodies in SSc patients. Sera from 45 SSc patients were tested in 15 pools from groups of three patients with the same phenotype. A sera pool from 12 healthy individuals was used as a control. Proteins of interest were identified by PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/16989806 mass spectrometry and analysed using Pathway Studio software. Results: We identified 974 and 832 protein spots in HEp-2 cell total and enriched nuclear protein extracts, respectively. Interestingly, a-enolase was recognised by immunoglobulin G (IgG) from all pools of patients in both extracts. Fourteen and four proteins were recognised by IgG from at least 75 of the 15 pools in total and enriched nuclear protein extracts, respectively, whereas 15 protein spots were specifically recognised by IgG from at least four of the ten pools from patients with unidentified ANAs. The IgG intensity for a number of antigens was higher in sera from patients than in sera from healthy controls. These antigens included triosephosphate isomerase, superoxide dismutase mitochondrial precursor, heterogeneous nuclear ribonucleoprotein L and lamin A/C. In addition, peroxiredo.
Bussone et al. Arthritis Research Therapy 2011, 13:R74 http://arthritis-research.com/content/13/3/RRESEARCH ARTICLEOpen AccessIdentification of new autoantibody specificities directed at proteins involved in the transforming growth factor b pathway in patients with systemic sclerosisGuillaume Bussone1,2, Hanadi Dib1,2, Mathieu C Tamby1,2, Cedric Broussard3, Christian Federici3, Genevi e Woimant4, Luc Camoin3, Lo Guillevin5 and Luc Mouthon1,2,5*AbstractIntroduction: Antinuclear antibodies (ANAs), usually detected by indirect immunofluorescence on HEp-2 cells, are identified in 90 of patients with RRx-001 systemic sclerosis (SSc). Thus, approximately 10 of SSc patients have no routinely detectable autoantibodies, and for 20 to 40 of those with detectable ANAs, the ANAs do not have identified specificity (unidentified ANAs). In this work, we aimed to identify new target autoantigens in SSc patients. Methods: Using a proteomic approach combining two-dimensional electrophoresis and immunoblotting with HEp-2 cell total and enriched nuclear protein extracts as sources of autoantigens, we systematically analysed autoantibodies in SSc patients. Sera from 45 SSc patients were tested in 15 pools from groups of three patients with the same phenotype. A sera pool from 12 healthy individuals was used as a control. Proteins of interest were identified by PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/16989806 mass spectrometry and analysed using Pathway Studio software. Results: We identified 974 and 832 protein spots in HEp-2 cell total and enriched nuclear protein extracts, respectively. Interestingly, a-enolase was recognised by immunoglobulin G (IgG) from all pools of patients in both extracts. Fourteen and four proteins were recognised by IgG from at least 75 of the 15 pools in total and enriched nuclear protein extracts, respectively, whereas 15 protein spots were specifically recognised by IgG from at least four of the ten pools from patients with unidentified ANAs. The IgG intensity for a number of antigens was higher in sera from patients than in sera from healthy controls. These antigens included triosephosphate isomerase, superoxide dismutase mitochondrial precursor, heterogeneous nuclear ribonucleoprotein L and lamin A/C. In addition, peroxiredo.
- 이전글Why Pharmacy Isn't any Buddy To Small Business 23.06.12
- 다음글Коса навыворот милые картинки 23.06.12
댓글목록
등록된 댓글이 없습니다.
